Bank of America 13F: Adds $82M to ALNY Stake

Bank of America Boosts Alnylam Stake

Bank of America filed a Form 13F with the Securities and Exchange Commission, revealing a sizable addition to its investment in Alnylam Pharmaceuticals (NasdaqGS: ALNY). According to the filing for the period ending May 18, 2026, the financial institution boosted its position by picking up an additional 281,735 shares. That move equals a 41.1% increase from the prior quarter, lifting the total share count to 966,912 shares. The reported value of the bank's stake reached approximately $280.9 million. Because 13F filings look backward at portfolio holdings from specific dates, this snapshot captures the fund's posture at that time and may not reflect its current positioning today.

Alnylam Stock Context and Market Standing

Shares of Alnylam Pharmaceuticals trade at $290.48. The biotechnology firm carries a market capitalization of roughly $32.7 billion and a trailing price-to-earnings ratio of 42.5, alongside a forward P/E of 19.6. Institutional investors monitor these valuation metrics closely as the company advances its pipeline of RNA interference therapeutics. The stock has experienced various shifts in institutional ownership over recent quarters, with several large asset managers trimming or expanding their exposure depending on their portfolio strategies.

Wall Street Analyst Views on Alnylam

Wall Street firms have kept a close eye on Alnylam's development pipeline, regularly adjusting targets as clinical updates emerge. On October 14, 2026, Citigroup maintained its buy rating while adjusting its price target to $320.00 from $340.00. On the same day, Wells Fargo maintained an equal-weight rating and set a target of $253.00. Earlier on October 8, 2026, RBC Capital kept an outperform rating with a $345.00 target, while JP Morgan maintained an overweight rating with a $369.00 target on September 30, 2026. HC Wainwright & Co. reiterated a buy rating with a $455.00 target on September 21, 2026, following an identical target affirmation earlier that month on September 2. Jefferies maintained a hold rating while lifting its target to $260.00 on September 8, 2026, and BMO Capital initiated coverage with an outperform rating and a $318.00 target on August 19, 2026. Across 26 analyst opinions, the stock holds a consensus buy rating and a mean price target of $371.35.

Inside Alnylam's Therapeutics Pipeline

Alnylam Pharmaceuticals discovers, develops, and commercializes RNA interference therapeutics for genetic and specialty diseases. Headquartered in Cambridge, Massachusetts, the firm markets several approved treatments, including ONPATTRO and AMVUTTRA for ATTR amyloidosis, Leqvio for cholesterol management, and GIVLAARI for acute hepatic porphyria, alongside an extensive clinical pipeline targeting various other conditions. The company's next earnings report is scheduled for October 29, 2026.

What to Watch Next for ALNY

Investors tracking Alnylam will look toward its upcoming financial results on October 29, 2026, for updates on revenue growth and product sales. Subsequent 13F filings from major institutional holders like Bank of America will provide further insight into how large funds adjust their weightings in the biotechnology sector. As always, these retrospective filings offer a window into past portfolio management rather than a real-time indicator of future stock performance.